Dr Rakesh Popat, Consultant Haematologist
Dr Rakesh Popat
Consultant Haematologist
Dr Rakesh Popat BSc, MBBS, MRCP, FRCPath, PhD
Consultant Haematologist
Dr Rakesh Popat
Consultant Haematologist BSc, MBBS, MRCP, FRCPath, PhD
Dr Popat is a recommended Consultant Haematologist
Areas of expertise
- Blood diseases (clinical haematology)
- Myeloma
- Haemato-oncology
- Blood cancer
- Bone marrow transplant
Recommendations for Dr Popat
These recommendations are for information purposes only. Doctors providing recommendations do so in good faith and are not responsible for clinical outcomes.
Recommended by:
byMr Sam Singh, Consultant Orthopaedic Foot & Ankle Surgeon
❝Dr Rakesh Popat is a great haematologist. He's very knowledgeable and has a very good bedside manner.❞
byMr Sam Singh, Consultant Orthopaedic Foot & Ankle Surgeon
❝Dr Rakesh Popat is a great haematologist. He's very knowledgeable and has a very good bedside manner.❞
Make an appointment
Address
-
HCA UK at University College Hospital
Grafton Way Building, 1 Grafton Way, London, WC1E 6AG
About Dr Rakesh Popat
GMC number: 4432920
Year qualified: 1997
Place of primary qualification: University of London
Areas of expertise
- Myleloma
- Lymphomas
- Thrombosis and embolism
Professional memberships
Articles by Dr Rakesh Popat
Characterisation of response and corneal events with extended follow-up after belantamab mafodotin (gsk2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial
Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (covid‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy.
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (mascot): an exploratory randomised phase 2 trial utilising a modified zelen design
Correction to: corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, dreamm-2 study
Corneal epithelial findings in patients with multiple myeloma treated with antibody–drug conjugate belantamab mafodotin in the pivotal, randomized, dreamm-2 study
Antibody–drug conjugate, gsk2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase i study
How to simplify the evaluation of newly introduced chemotherapeutic interventions in myeloma
